MREO — Mereo BioPharma Group plc

Nasdaq · Health Care · Pharmaceuticals · CIK 1719714 · United Kingdom
Last close
$0.33
Market Cap
$53.26M
52W High
$0.42
52W Low
$0.22
ADV30
2,519,953
Next earnings
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism; Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Etigilimab, an IgG1 monoclonal antibody which binds to the human TIGIT receptor on immune cells for the Treatment of advanced solid tumors; and Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 -8,671,000 -6,719,000 40,614,000 36,223,000 6,560,000
Dec 2025 0 0 -7,917,000 -7,351,000 45,917,000 40,992,000 5,001,000
Sep 2025 0 0 -9,569,000 -7,024,000 53,602,000 48,698,000 7,004,000
Jun 2025 500,000 368,000 -9,754,000 -14,616,000 62,631,000 56,125,000 8,454,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-30,971,000
Investing CF
$-20,000
Financing CF
$327,000
CapEx
$-320,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-0.35
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-501,018,000
Inventory
Receivables
$1,983,000
ST Investments
EBIT TTM
$-41,623,000
Pretax Income TTM
$-41,878,000
Interest Exp TTM
$255,000
Analysts
6

Yahoo Snapshot (yfinance, live)

Total Revenue
$500,000
EBITDA
$-35,577,500
Free Cash Flow
Enterprise Value
$185,882,336
Total Cash
$36,223,000
Total Debt
$0
Shares Out
159,618,609
Trailing EPS
$-0.20
Book Value
$0.21
ROE
-75.9%
ROA
-41.6%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 500,000 -38,257,000 -41,878,000 45,917,000 5,001,000 -30,971,000
Dec 2024 0 -45,715,000 -43,253,000 76,390,000 15,421,000 -32,834,000
Dec 2023 10,000,000 -27,136,000 -29,466,000 66,499,000 15,962,000 -21,132,000
Dec 2022 0 -52,698,000 -42,220,000 77,413,000 26,011,000 -48,821,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.04

Peers — same industry

TickerNameMarket CapLastDaily %
KZR Kezar Life Sciences, Inc. $53.86M $7.29
ACTU ACTUATE THERAPEUTICS, INC. $52.64M $2.20
SCYX SCYNEXIS INC $54.10M $0.68
GOSS Gossamer Bio, Inc. $51.63M $0.22
IBO IMPACT BIOMEDICAL INC. $55.20M $0.51

News headlines (Yahoo Finance, 1h cache)

European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading
2026-05-26 15:09 · Yahoo
European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading
2026-05-22 15:06 · Yahoo
European Equities Traded in the US as American Depositary Receipts Open Week Tracking Higher in Monday Trading
2026-05-18 15:11 · Yahoo
European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading
2026-05-13 15:12 · Yahoo
European Equities Traded in the US as American Depositary Receipts Decline Sharply in Tuesday Trading
2026-05-12 15:14 · Yahoo
Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
2026-05-12 11:30 · Yahoo
European Equities Traded in the US as American Depositary Receipts Start Week on Flat Note in Monday Trading
2026-05-11 15:05 · Yahoo
European Equities Traded in the US as American Depositary Receipts Climb Sharply Higher in Wednesday Trading
2026-05-06 15:10 · Yahoo
European Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading
2026-05-05 15:08 · Yahoo
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
2026-04-30 15:06 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.